Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine + Carboplatin for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Mar 2026: Trial registered, NCT07495124
  2. 16 Sep 2026: Trial started, NCT07495124

The trials

NCT07495124: IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

State
Under way
Phase
Phase 2
People
26 planned
Started
16 Sep 2026
Primary completion
29 Sep 2027
Arms
Treatment (carboplatin, IGFBP-2 vaccine)
Results
None posted
  1. 27 Mar 2026: Trial registered
  2. 16 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.